The 'protein only' hypothesis postulates that the prion, the agent causing transmissible spongiform encephalopathies, is PrP(Sc), an isoform of the host protein PrP(C). Protease treatment of prion preparations cleaves off approximately 60 N-terminal residues of PrP(Sc) but does not abrogate infectivity. Disruption of the PrP gene in the mouse abolishes susceptibility to scrapie and prion replication. We have introduced into PrP knockout mice transgenes encoding wild-type PrP or PrP lacking 26 or 49 amino-proximal amino acids which are protease susceptible in PrP(Sc). Inoculation with prions led to fatal disease, prion propagation and accumulation of PrP(Sc) in mice expressing both wild-type and truncated PrPs. Within the framework of the 'protein only' hypothesis, this means that the amino-proximal segment of PrP(C) is not required either for its susceptibility to conversion into the pathogenic, infectious form of PrP or for the generation of PrP(Sc).
Introduction
A wealth of data supports the 'protein only' hypothesis (Griffith, 1967) which proposes that the prion, the agent responsible for transmissible spongiform encephalopathies (TSEs), is a modified, pathogenic form of a constitutive host protein and that it multiplies by converting the normal form into a likeness of itself (Prusiner, 1991) . The host protein, PrPC, and its modified form, PrPsc, have been isolated; both are encoded by the same gene (Basler et al., 1986) and are believed to be conformational isomers. Copurification experiments demonstrate physical linkage of infectivity with PrPsc (Bolton et al., 1982; Gabizon et al., 1988) . A scrapie-specific nucleic acid has never been detected (Kellings et al., 1993) , arguing against the virus (Diringer et al., 1994) and virino (Dickinson and Outram, 1988) hypotheses. Because the ratio of infectious units to PrPsc molecules is only~1:100 000 (Bolton et al., 1991) , the structure of the prion protein (PrP) molecule actually associated with infectivity cannot be inferred definitively. For this reason, and because specific infectivity can vary considerably, the PrP species responsible for infectivity is presently better designated as PrP* (Weissmann, 1991) ; it may or may not be identical with PrPsc, the major species that has been characterized chemically and physicochemically. If it is identical, the low specific activity could be due to low efficiency of infection or to the infectious unit being an aggregate of a large number of PrPsc molecules.
Genetic evidence linking PrP to prion diseases is compelling. Ablation of the PrP gene renders mice resistant to experimental scrapie and precludes replication of the infectious agent; reintroduction of PrP transgenes restores susceptibility to scrapie (Bueler et al., 1993; Sailer et al., 1994) . The so-called species barrier, which hinders prion transmission from one host species to another, is overcome by introducing PrP transgenes from the prion donor to the recipient (Prusineretal., 1990; Bueleretal., 1993) . Remarkably, all familial cases of TSE in man are probably linked to one of many possible mutations in the PrP gene (Baker and Ridley, 1992) ; these mutations are thought to facilitate occasional spontaneous conversion of PrPC to PrPsc (or PrP*), which is then followed by the autocatalytic process.
PrPc and PrPsc are chemically indistinguishable (Stahl et al., 1993) but differ in their secondary structure and physico-chemical properties. PrPC has a very low and PrPsc a high content of ,8-pleated sheet structure Pan et al., 1993) . Under conditions where PrPc is readily degraded by proteinase K, PrPsc is partially resistant.
About 60 N-terminal residues are cleaved off and the remainder ofthe molecule is quite stable. Under these conditions of protease treatment, prion preparations retain full infectivity. It has been shown earlier, by introducing a truncated version of the PrP gene into scrapie-infected N2A neuroblastoma cells, that PrPc devoid of 66 N-terminal amino acids can still give rise to PrPsc; however, it was not determined whether infectivity was associated with the truncated PrPsc molecule (Rogers et al., 1993) .
We now show that introduction of truncated PrP transgenes encoding PrPc devoid of as many as 49 aminoproximal amino acids into PrP knockout mice restores susceptibility to scrapie, allows prion propagation and leads to accumulation of PrPsc. Within the framework ofthe 'protein only' hypothesis, this means that the amino-proximal segment of PrPc is required neither for conversion into the pathogenic, infectious form of PrP nor for the generation of PrPsc.
Results
Introduction of transgenes encoding wild-type murine PrP into Prnp0"0 mice restores susceptibility to mouse prions We have shown earlier that Pmp010 mice are resistant to experimental scrapie and do not propagate the infectious Fig. 1 . Wild-type and mutant PrP-encoding genes. (A) Maps of constructs encoding wild-type PrP. Cos6. 11, a cosmid-derived clone comprising three exons (El, E2 and E3), two introns (I1 and 12), 6 kb of 5'-and 17 kb of 3'-flanking regions; phgPrP, as before, but lacking intron 2 and with only 2.2 kb of 3-flanking region; pPrPcDNA, as phgPrP, but lacking both introns. (B) Wild-type and mutant constructs derived from phgPrP. The boxes represent the part of the transcription unit comprised of exons 2 and 3. Open boxes, 5'and 3'-non-coding; hatched, 5' and 3' signal sequences; lightly stippled, coding sequence of mature PrP; dark stippled boxes and underlined sequence, octa repeats; horizontal black bar, protease-sensitive in PrPSC; arrowhead, beginning of the sequence resistant to protease in PrPSC; *, deletion breakpoints. (C) Flowsheet for the construction phgPrP and pPrPcDNA; details are given in Materials and methods. (D) Detailed view of phgPrP showing the origin of the various segments and the primers (arrows) used in various PCRs. Hatched box, 5'-flanking region; light stippled, non-coding regions; heavy stippled, ORF; heavy lines, intron or 3'flanking regions. agent (Bueler et al., 1993; Sailer et al., 1994) . Moreover, breeding multiple hamster Prnp transgenes into Pmp010 mice rendered the latter highly susceptible to hamster prions but much less so to mouse prions. We now undertook to introduce genes encoding wildtype and mutated murine PrP into Pmpolo mice by transgenesis. For this purpose, we examined several PrPencoding constructs for their efficacy in restoring susceptibility to scrapie. Wild-type mice containing multiple Prnp transgenes have been generated previously by injecting 40 kb cosmid DNA containing genomic Prnp into onecell embryos of wild-type mice, and efficient expression of PrP was achieved (Scott et al., 1989; Hsiao et al., 1990) . The mouse PrP gene contains an upstream intron of 2 kb and a downstream intron of 6-12 kb (Westaway et al., 1994a) . In order to facilitate mutagenesis, we generated a PrP-encoding construct from which the large intron ('half-genomic construct' or phgPrP) or both introns ('cDNA construct' or pPrPcDNA) were deleted and which contained 5.5 kb of 5'and 2 kb of 3'-flanking sequence (Figure lA ). These constructs, as well as the Prnpcontaining cosmid DNA (cosmid cos6.IflnJ4 ; Westaway et al., 1991) were introduced into Prnp010 or Prnp0l+ mice by nuclear injection. Founders were identified and bred to yield Prnpolo lines homozygous or heterozygous for the PrP-encoding transgene array.
PrP expression in the brain was monitored by Northern analysis (Table I) . In all but one of the six lines carrying half-genomic Prnp transgenes tested, PrP was expressed. In contrast, the cDNA construct, in all eight lines tested, even in those (tgb9/+, tgb24/+) with very high transgene copy numbers (> 150 copies), showed no detectable levels of PrP protein in the brain and only very weak (tgb24/+) or no expression of PrP RNA (data not shown). The one line of cosmid transgenic mice examined showed efficient PrP expression, as expected from previous work (Westaway et al., 1991) . These results, in agreement with earlier data (Scott et al., 1989) , show that the presence of at least one intron is essential for the efficient expression of a PrP-encoding transgene under the control of its own promoter. A requirement of introns for efficient (Brinster et al., 1988) and/or tissue-specific (Lozano and Levine, 1991) expression of some transgenes has been described previously. Two half-genomic (tgal9/+; tga2O/+) mouse lines and one cosmid mouse line (tgc35/+), all with similar gene copy numbers of -30-40, were analyzed in more detail. As shown in Figure 2 and Table I, all three lines overexpressed PrP in the brain at levels ranging from~3-to 4-fold and 4to 5-fold (tgal9/+ and tgc35/+ respectively) to 6to 7-fold (tga2O/+) of those observed in wild-type P)np+/+ animals. The distribution of PrP transcripts in the brains of the two half-genomic and the cosmid lines was analyzed by in situ hybridization of brain sections with a PrP antisense riboprobe ( Figure 3 ). Overall levels of PrP RNA were higher in the brains of transgenic than in those of wild-type animals. The expression patterns were similar in transgenic and wild-type mice, with highest PrP RNA levels in the hippocampus ( Figure 3A , C and E) and the cerebellum ( Figure 3B , D and F). In some areas, like the molecular layer of the cerebellum, PrP RNA-positive cells were clearly visible in transgenic but only very faintly in wild-type mice, supporting the notion that expression of PrP RNA was generally increased. Interestingly, however, PrP RNA was not detected in the Purkinje cells of animals carrying half-genomic transgenes (tga19, Figure 3F ; tga2O, not shown), while it was abundant in Purkinje cells of wild-type and cosmid transgenic mice ( Figure 3B and D). This suggests that one or more control elements responsible for the specific expression of PrP in Purkinje cells are absent from the half-genomic construct.
Some animals containing the cosmid transgene (tgc35/ +; tgc35/c35, Prnp allele b) gradually developed paresis of their hind-limbs as early as 4-6 months after birth. Similar symptoms in mice overexpressing this as well as other types of Prnp cosmid transgenes have been described earlier (Westaway et al., 1994b) . Animals expressing halfgenomic PrP-A, at even higher levels in the brain (tga2O/+, tga20/tga20), revealed no obvious pathological phenotype.
This difference could be due to the different allelic nature of the two transgenes (Carlson et al., 1988) , to differences in expression patterns or to overexpression of an unidentified gene product encoded by sequences present in the cosmid but not in the half-genomic construct. Because these symptoms were found in several independent PrP cosmid transgenic mouse lines, it seems unlikely that they were due to position effects of the transgene integration.
To determine whether the half-genomic construct could restore susceptibility to scrapie, mice hemizygous for the half-genomic tga2O/+ and tgal9/+ transgene insertion were inoculated with mouse prions. As positive controls, tgc35/+ animals hemizygous for the cosmid transgene array and Prnp+'l mice of comparable genetic background to the Prnp°/°mice used for the generation of the transgenic lines (offspring of C57/Bl6X 129/SV crosses; Bueler et al., 1992) were inoculated similarly. Negative controls were Pmp0/0 mice inoculated with prions and mock-inoculated transgenic animals. Results are compiled in Figure 4 . The negative control groups remained free of scrapie during the time of observation, for up to 500-600 days postinoculation (data not shown). One mock-inoculated tga20/ + animal died 538 days p.i., after showing kyphosis and tremor, symptoms which occur in scrapie-infected but occasionally also in uninoculated aging mice; it was not analyzed further.
Scrapie-inoculated mice expressing the half-genomic construct or the cosmid displayed typical scrapie symptoms, such as hind-limb paresis, foot-clasp reflex, kyphosis, ataxia, disorientation and minced gait. Incubation times to the occurrence of first symptoms as well as to the terminal state (Table I) were shorter than in the wild-type control group, namely 68 ± 10 days for tga2O/+ and 100 ± 17 days for tgal9/+ (the two lines expressing the half-genomic transgene) and 130 ± 7 days for tgc35/+ (the line canfying the cosmid), as compared with 166 ± 8 days for wild-type mice. In addition, the duration of clinical disease was greatly decreased in the transgenic animals: in the tga2O/+ line, terminal disease occurred as early as 4 + 2 days after the observation of the first symptoms, as compared with 35 + 12 days in M.Fischer et a!. Fig. 2 . PrP mRNA and protein levels in brains of mice transgenic for wild-type and mutant PrP-encoding genes. (A) Northern blots were performed on 10 ,ug of total RNA as described in Materials and methods. PrP: the labeled probe corresponded to a region of the Prnp gene deleted in Prnp010 mice. Actin: the filter was stripped and rehybridized with a chicken P-actin cDNA probe. (B) Western blots of total mouse brain homogenates. One half mouse brain was homogenized in 1.35 ml of 0.5% SDS, 50 mM Tris-HCI (pH 6.8), 5 mM EDTA, 0.25 M PMSF, and 200 ,l of lysate was mixed with 500 gl of SDS loading buffer (Laemmli, 1970) without reducing agent. Samples (20-40 gl) were electrophoresed through a 12.5% polyacrylamide gel. Western blotting was carried out as described using antiserum R073 (lanes 1-6), 1B3 (lanes 7-14) or R3430 (lanes 15-21) and developed with the ECL system. All mice were hemizygous for the mutant alleles and Prnp010, except for the wild-type (wt). the wild-type group. Furthermore, shorter incubation times correlated with higher expression levels of PrPc when lines tgal9/+ and tga20/+ were compared, consistent with an inverse correlation between these two parameters, as suggested earlier (Scott et al., 1989; Bueler et al., 1994) .
Because tga2O mice showed such a short incubation time compared with the usual wild-type indicator mice, we explored the possibility of using them for prion titration by the incubation time assay . The titer of a prion preparation was determined by end point titration in tga2O mice (Reed and Muench, 1938) . Table  II shows the relationship between incubation period and inoculated dose; the data were used to determine the parameters of the equation: loglO(titerXdilution) = a-b (incubation time).
Generation and characterization of mice transgenic for mutant PrP genes
The observation that moderate treatment of preparations of scrapie agent with proteinase K removes amino acids 23-80 of mouse PrPSc (Hope et al., 1988) without abrogating infectivity (Neary et al., 1991) suggested that, within the framework of the 'protein only' hypothesis, the aminoproximal deletion mutants described above may be functional, provided that the truncated protein is susceptible to conversion. Moreover, a human PrP allele with a nonsense mutation in codon 145 has been found in a patient who suffered from neurodegenerative disease and had amyloid plaques containing PrP truncated at the cognate position (Kitamoto et al., 1993) . This suggested that such truncated PrP might also be pathogenic.
Deletion of codons 23-88 of the hamster PrP gene as well as truncation of the C-terminal codons downstream of the attachment site for the GPI-anchor did not preclude conversion of PrPc to PrPSc in scrapie-infected neuroblastoma cells (Rogers et al., 1993) . However, protease resistance of PrP is not necessarily linked to scrapie infectivity (Manuelidis et al., 1987; Xi et al., 1992; Pocchiari, 1994) and is therefore not a reliable marker for this property.
In order to define the requirements of PrP for conferring susceptibility to scrapie and promotion of prion replication, N-and C-terminal deletion mutants of the PrP gene were constructed and mice transgenic for these genes were assessed for susceptibility to scrapie, propagation of prions and, where appropriate, formation of PrPSC.
Four constructs, based on the half-genomic vector (Figure 1) , were prepared and introduced as transgenes into Pmp010 mice. The founders were mated to Pmp010 partners and the hemizygous offspring were tested for the presence and the expression of the PrP transgenes (Table  I, encoding amino acids 32-80 (inclusive) was deleted but the codons for the signal sequence and nine additional amino acids were retained to ensure correct processing and localization in the cell. (ii) Construct e (pPrPANco): the sequence encoding two of the five copies of the octa repeat PxGGxWGQ (from amino acid 68 to 83 inclusive) was deleted. (iii) Construct f (pPrP-C-term): the sequence encoding amino acids 144 (inclusive) to the end was ablated by fusing codon 143 to the termination codon of the PrP reading frame. (iv) Construct g (pPrPAN&Cterm): the deletions of constructs d and f were combined, to give a sequence encoding a mature protein of 73 amino acids. Most animals carrying the PrPAN-term and PrPANco transgenes expressed them at both the RNA (Figure 2A ) and protein level ( Figure 2B ). As expected, the protein encoded by the PrPAN-term gene showed distinctly higher mobility than wild-type PrP (Figures 2B and 4) about half the wild-type PrP level. tgal9/+ and tga20/+ are Prnp010 mice containing -30 copies of the hgPrP construct and expressing -3-4 and 6-7 the wild-type level of PrP, respectively. Intracerebral inoculation with mouse scrapie prions was as described (Bueler et al., 1993) . Scrapie was diagnosed if mice showed three or more scrapie-specific symptoms (decreased motor activity, hind-limb paresis, foot-clasp reflex, kyphosis, ataxia, disorientation, minced gait). The horizontal bars indicate for each mouse the time elapsed from diagnosis until the terminal stage of disease (immobility or inability to procure food or drink). In all cases, 30 gl of the indicated dilution of a 10% brain homogenate were injected intracerebrally into tga2O/tga2O mice. aTiters were determined by the incubation time assay , using the relationship y = 14.37-1.lx, where v is log LD50 and x is incubation time (days) to terminal disease; this relationship was determined from the end point titration of experiment 1.
PrPANco product showed only a slight decrease in mobility (not detectable in the analyses shown). In contrast, the mice transgenic for PrPAC-term and PrPAN&C-term expressed lower levels of PrP transcripts per transgene copy than wild-type animals and no PrP was detected in their brains. In some lines carrying 200 or more transgene copies (tgf6O/+, tgf67/+, tgg46/+), mRNA was present at levels similar to wild-type animals, and yet it was not possible to detect PrP in brain extracts using polyclonal antibodies directed against full-length murine PrP (data not shown) or a polyclonal antiserum directed against a peptide present within the expected mutant proteins ( Figure  2B, lanes 15-21) .
Inoculation of mice carrying mutant PrP transgenes with prions
Lines of Pmpolo mice carrying a high copy number of mutated transgenes were chosen for inoculation experiments (Table I ). In the case of PrPAN-term, tgdl2/+ mice with copy numbers of 30-40 in the hemizygous state expressed truncated PrP at~10-12 times wild-type. The lines tgel9h/+ and tgel9l/+, with~150 and 15 copies of the PrPANco gene, expressed -3-4 times and twice wildtype levels of truncated PrP. In the case of lines tgf67/+ and tgg46/+ carrying~200 copies of PrPAC-term and PrPAN&C-term respectively, PrP RNA was expressed at high levels but PrP could not be detected.
Inoculation was with mouse prions as above; the endpoint of the experiment was the appearance of terminal scrapie symptoms, at which time the animals were sacrificed. As shown in Table I , both N-proximally truncated transgenes were capable of restoring susceptibility to scrapie in Prnp010 mice. The two lines expressing PrPANco, as well as those expressing wild-type PrP, showed incubation times that appeared to be dependent on PrP levels: 104 ± 9 days and 72 ± 16 days for tgel9l/+ and tgel9h/+ animals, respectively, values very close to those of tgal9/+ and tga20/+ animals (100 ± 17 days and 68 ± 10 days respectively (Table I ). The two lines expressing PrPAN-term transgenes, tgdll/+ and tgdl2/+, displayed incubation times of 103 ± 11 days and 89 ± 12 days, respectively. Both the determination of PrP levels In all cases, 30 g1 of the the indicated dilution of a 10% brain homogenate were injected intracerebrally in CD-1 mice. aTiters were determined by the incubation time assay as described previously (Bueler et al., 1993 ; see Table II ). and the measurement of incubation times, due to the small numbers of samples tested in both cases, are only approximate.
In contrast to the results outlined above, no scrapie symptoms were observed in scrapie-inoculated animals transgenic for either AC-term or AN&C-term transgenes (>270 days p.i. at the time of writing). This finding is not unexpected in view of the lack of detectable PrPC in these lines. Transmission experiments to determine whether prion replication has occurred in the brains of these animals have been initiated and have failed to demonstrate the presence of scrapie infectivity up to 270 days p.i.
Mock-inoculated N-terminal mutant mice remained free of scrapie symptoms for the entire observation period (>290 days p.i. at the time of writing) (Table I) , except for one mock-inoculated tgdl2/+ animal which was found dead at 101 days p.i. after showing kyphosis and footclasp reflex. Histopathology of the poorly preserved brain was inconclusive.
Determination of scrapie infectivity in brains of transgenic mice expressing truncated and normal PrP
We assayed scrapie infectivity on CD-1 wild-type mice, because the tga2O assay system had not been available initially. As shown in Table III , titers of brain homogenates from scrapie-infected, terminal or close to terminal mice carrying the wild-type hgPrnp transgenes (tga2O), or the transgenes with the large (tgdl2/+) or small (tgel9h/+) deletion were all in the range 6-8 log LD50 units/ml of 10% homogenate. These results are supported by similar data in Table II (the 10-' dilutions used for inoculation are, however, outside the linear range of the assay and thus do not yield absolute values).
From these data, it is clear that PrP devoid of amino acids 32-80 is able to restore the capacity of propagating mouse scrapie prions. Because of the imprecision of the assay and because incubation times could be prolonged when the PrP sequence in prion donor and recipient is different (Scott et al., 1989; Prusiner et al., 1990; Bueler et al., 1993) , it is not possible to conclude whether or not the truncation of PrP diminished its efficacy to some degree.
Determination of protease-resistant PrP in mice overexpressing PrP A pathognomonic feature of prion diseases is the accumulation of PrPsc, defined by its partial resistance to limited protease digestion, in scrapie-diseased brains. Protease treatment of mouse PrPsc gives rise to PrP27-30, a truncated form of the mature protein, lacking (in addition to the signal sequence) 58 N-terminal amino acids, from Lys23 to Trp8O (Hope et al., 1988) . The large N-terminal mutant gene PrPAN-term was designed to yield a protein with a similar primary structure to PrP27-30, except for the retention of the first nine residues of the mature sequence, Lys23-Trp3I (Figure 1 ). Therefore, it was of interest to determine whether scrapie infection of mice carrying the PrPAN-term transgene would lead to accumulation of protease-resistant mutant PrP and whether such molecules would be similarly truncated by protease treatment.
As shown earlier, PrPsc can be pelleted from detergenttreated brain homogenates by centrifugation at 100 000 g, while PrPc remains in the supematant . Brain homogenates were prepared from healthy and scrapie-sick animals, and samples were subjected to proteinase K digestion and centrifuged at 100 000 g. Aliquots of the untreated, total homogenates equivalent to 0.1 mg of brain tissue and pellet fractions equivalent to 1 mg of brain tissue were analyzed by immunoblotting ( Figure 5 ). As reported earlier, the total PrP level of wild-type brain increased S5-fold in scrapie-inoculated brains of terminal animals ; however, no such increase was found in the brains of PrP-overexpressing transgenic animals, either in the case of full-length or of the AN-term truncated PrP ( Figure 5 ). Unexpectedly, in PrP-overexpressing scrapie-infected brains, the level of PrPSC was only about half the wild-type level, in the case of full-length and only~25% in the case of truncated PrP. Thus, in brains of terminally scrapie-sick wild-type animals, PrPsC was~50% of total PrP, while in animals overexpressing PrP this value ranged from 3 to 10%.
The electrophoretic mobility of the amino-proximally truncated PrP lacking amino acids 32-80 from a tgdl2/+ animal (Figure 5, lanes 7 and 8) is, as expected, greater than that of wild-type PrP (lanes 1-6) ; however, proteinase K-treated PrPSC from wild-type (lanes 10, 12 and 14) and mutant (lanes 16) have a similar mobility. This suggests that the primary structure of truncated PrPSC encoded by PrPAN-tern is similar to that of the protease-resistant core of normal PrPSc.
Discussion
The finding that mice devoid of PrP were viable and resistant to scrapie opened up the possibility of carrying out reverse genetics on the Prnp gene with regard to its function in prion diseases.
To facilitate the introduction of mutations, we prepared a mini-Prnp gene ('half genomic Prnp') lacking the large intron, and determined its capacity to restore expression of PrP and susceptibility to mouse scrapie. The expression pattern generated by the mini-Prnp gene in brain differed slightly from that in wild-type mice or mice transgenic for the complete Prnp gene introduced as a cosmid clone, in that PrP mRNA in Purkinje cells was undetectable. This suggests that the mini-gene lacks a cell-specific enhancer which could be located in the large intron or in 3'-flanking regions present in the cosmid clone but not in the truncated construct. Removal of both introns precluded expression altogether.
Mice carrying -60 copies of the half-genomic sequence hgPrnp, such as tga2O/tga2O, expressed~10 times the normal PrP level and were very susceptible to scrapie: the incubation time to terminal disease after inoculation with~106 LD50 units of mouse prions was only 61 ± 3 days, as compared with 149 ± 12 days for a standard wild-type mouse such as CD-1. Because of the short and reproducible incubation times, we have been using these mice routinely for titering mouse prion levels (Brandner et al., 1996) . We obtained transgenic mice which overexpressed PrP with amino-proximal deletions at levels commensurate with those of tga2O/+ mice; however, no PrP expression was found in lines of mice carrying up to~200 genes encoding PrP truncated at residue 144, even when the cognate mRNA was expressed at wild-type level. Because the C-terminal truncation removed the domain responsible for anchoring PrP to the cell surface, the protein may have been secreted and degraded rapidly. It is not clear why in the case of a patient heterozygous for a Prnp gene encoding PrP with the analogous deletion (Kitamoto et al., 1993) the amyloid plaques contained exclusively a truncated form of PrP. Possibly, the truncated PrP was not the product of the mutated allele, but a proteolytic fragment derived from the product of the normal allele. Similarly truncated fragments have been found in amyloid of Gerstmann-Straussler-Scheinker disease (GSS) cases and shown to be derived from full-length PrP, albeit with missense mutations (Tagliavini et al., 1994) .
Curiously, all PrP-overexpressing mice showed lower absolute levels of PrPSC at the final stages of disease than wild-type mice, resulting in a ratio of PrPSC to total PrP of~0. 1 or less in overexpressing animals and~0.5 in wildtype mice. This may come about because accumulation of PrPSC is a time-dependent process and PrP-overexpressing mice die early on. In view of our earlier finding that mice containing a single copy of the Prnp gene have incubation times of .41 weeks and already have high levels of PrPSC after 24 weeks, when they are still months away from showing scrapie symptoms, and of reports that mice (Hsiao et al., 1994) and humans (Collinge et al., 1995) succumbing to prion disease may be devoid of detectable PrPsC, it seems likely that accumulation of high levels of
PrPSC is neither necessary nor sufficient for disease and death. It should, however, be noted that because the detection of infectivity is orders of magnitude more sensitive than that of PrPSC, it is possible that the prion is associated with a subset of protease-resistant PrP which we have previously dubbed PrP* (Weissmann, 1991) .
The hypothesis that scrapie pathology is due to depletion of PrPc is not supported by the finding that PrPC-overproducing mice succumb to disease rapidly, although relatively little of it is converted to PrPSc. It has been reported that moderate protease treatment of scrapie-infected hamster brain homogenates resulted in little if any decrease of infectivity (McKinley et al., 1983) , and that~66 amino acids were cleaved off hamster PrPSc under such conditions. Similar conclusions can be drawn for mouse PrPSc (Hope et al., 1988; Neary et al., 1991) . If the 'protein only' hypothesis is correct, this means that the protease-susceptible residues are not required for the conversion of mature full-length PrPc into PrPSc. Our experiments comparing mice expressing high levels of wild-type PrP or PrP lacking residues 32-80 show that both are susceptible to scrapie and capable of allowing efficient propagation of the infectious agent. Our data do not allow us to conclude whether the somewhat longer incubation times in the case of the shortened PrP molecules are due to experimental variation or to a moderately lower efficiency of the shortened molecule in mediating disease. In order to clarify this point, it will be necessary to replace the wild-type Prnp gene by the mutated version using homologous recombination, so as to ensure identical gene copy numbers and genetic environment. Such experiments are currently underway.
In any event, it is clear that, by and large, the course of the disease and the levels of PrPSc attained are very similar in mice carrying similar copy numbers of truncated or wild-type PrPC. Within the framework of the 'protein only' hypothesis, this means that not only is proteasetruncated PrPSc capable of converting PrPc into PrPSc, but that PrPC devoid of 49 amino-proximal residues is subject to conversion by full-length PrPSc into a shortened version of PrPSc with the same susceptibility to protease as its normal counterpart.
Materials and methods

DNA constructions
DNA constructions (Figure 1 ) were carried out according to standard cloning protocols (Ausubel et al., 1987 : Sambrook et al., 1989 using the following starting DNAs: cos6.I/LNJ-4 (Westaway et al., 1994a) ; pNZWBamHI (containing an 8.9 kb segment of the mouse Prnpa gene; Bueler et al., 1992) ; pPrPS4 (provided by D.Westaway) consisted of the 7.6 kb XbaI fragment from cos6.I/LNJ-4 comprising Prnp exons 1 and 2 in the XbaI site of pBluescribe; cDNA-NMRI was amplified from total brain cDNA from NMRI mice using Vent DNA polymerase (Biolabs), the previously described primer P4 (Bueler et al., 1992) and primer prc5' (5 'GTCGGATCAGCAGACCGATTCTGGGCGCT3').
Plasmids encoding wild-type and mutant PrPs were constructed as follows.
pPrPEIilE23RI. The 3 kb Kpnl-BamHI fragment from pPrPS4 (com- prising exons and 2. intron 1 and part of the promoter) was isolated. cDNA-NMRI was digested with EcoRI and partially with Kpnl to yield a 1.3 kb fragment. The two fragments were joined to dephosphorylated BamtHI-and EcoRI-cleaved pBluescript (Stratagene). pPRPHG. The NotI-BspEI 5.5 kb fragment from cos6.I/LNJ-4 (comprising part or all of the Prnp promoter), the 3.5 kb NarI-BspEI fragment from pPrPE i E23R (containing exons 1 and 2, the coding region of exon 3 as well as intron 1) and the 3 kb Narl-SalI fragment of pNZW BamnHI (comprising the 3' end of Prnp) were joined to Notl-and Sallcleaved, dephosphorylated pBluescript in a four-way ligation. pPrPPEJ23RI. The 1.4 kb TfiI-EcoRI fragment of NMRI-cDNA (comprising exons 1. 2 and 3 up to the EcoRI site in the 3' non-coding region), the 157 bp Tfil-BspEI fragment from pPrPS4 (comprising the promoter sequences proximal to exon 1) and the 5.5 kb NotI-BspEI fragment from cos6.IILNJ-4 (containing the promoter) were joined to NotI-and EcoRI-digested. dephosphorylated pBluescript in a fourway ligation.
pPrPcDNA. The 6 kb EcoRI fragment from pPrPPE123RI (part of the promoter, exons and 2, the coding region of exon 3 as well as intron 1) was ligated to a dephosphorylated 6 kb EcoRI fragment from PrPHG (comprising the plasmid backbone as well as promoter and 3 '-untranslated sequences). pPrPANco. pPrPHG was digested with NcoI and religated. Resulting clones were screened for the presence and correct orientation of the fragment comprising exon 1, and the absence of the small Ncol fragment derived from exon 3. pPrPAN-terni. A PCR product was prepared using pPrPHG as template, primer prBspE5' (5 'caagcattaagccagtccggagcggtga3'). the mutation primer prA32-80 (5'tccaccgccatggggttgcccccaccctccaggct3') and cloned Pfui DNA polymerase (Stratagene). The 2 kb BspEI-NcoI fragment of this PCR product (comprising exon 1, intron I and exon 3 up to the deletion breakpoint) was joined to two fragments derived from pPrPHG, the 9 kb BspEI-Sall fragment (comprising the vector backbone and the PrP promoter) and the 3 kb NcoI-SalI fragment (comprising the 3' end of the half-genomic gene). pPrPAC-termtl. A PCR product was prepared using pPrPHG as template, primer prBspe5' (5'caagcattaagccagtccggagcggtga3') and the mutation primer prAC145 (5'cctccctcagtcgttgccaaaatggatcat3'). The 2.1 kb BspEI fragment of this product (containing exon 1, intron 1, exon 2 and the ORF of the mutated gene), the 9 kb BspEI-SalI (comprising the vector backbone and the PrP promoter) and the 2.7 kb StuI-SalI fragment (containing the 3' end of pPrPHG) of pPrPHG were joined in a threeway ligation. pPrPAN&C-term. All steps were carried out as for pPrPAC-term, except that the template for PCR was pPrPAN-term rather than PrPHG.
Plasmid DNA from E.coli XLl-blue (Stratagene) was purified using the Qiagen purification system. Linear amplification DNA sequencing (PCR sequencing) was carried out essentially according to Adams and Blakesly (1991) .
Generation of transgenic mice
Plasmid DNA was digested with NotI and Sall (only with Notl in the case of the cosmid), heated for 5 min at 65°C and electrophoresed through a %lc agarose gel (Seakem GTG; FMC BioProducts, Denmark). The PrP insert was purified using the Prep-A-Gene DNA extraction kit (Bio-Rad, USA). diluted to 1-2 ng/,ul with TE buffer (10 mM Tris-HCI pH 7.5. 0.5 mM EDTA), filtered through a Micropore filter (Millipore Ultrafree MC 0.45 pm) pre-rinsed twice with TE buffer. Microinjection into oocytes and re-implantation were as previously described (Brinster et al., 1985; Wilmut et al., 1991) .
PCR for the detection and quantitation of transgenes
Prnpo) and Prnp+ alleles, both transgenic and resident, were detected and quantified by a modification of a previous protocol (Biueler et al., 1992) . One microlitre of either purified genomic DNA or crude tail lysate (Laird et al., 1991) was added to 25 ,ul of PCR mix [50 mM KCI, 10 mM Tris-HCI (pH 9), 1.5 mM MgCl2, 2% deionized formamide, 0.1% bovine serum albumin (BSA), 0.1% Triton X-100, 0.5 ,uCi [aX-32P]dATR 0.2 mM each of dATP, dCTP, dGTP, dTTP, 0.7 ,uM of each primer and 0.6 units of Taq DNA polymerasel. Three primers were used to detect transgenes simultaneously and, as internal standard, the two Prnpo alleles P3 (specific for Prnpo) and PlO (specific for Prnp+) (Bijeler et al., 1992) and prPrP3'nc (5'ataacccctcccccagcct3') (complementary to both Prnp+ and Prnpo). The primer prPrP3'nc is proximal to the coding region of PrP, resulting in products of 350 bp for the Prnp(-specific signal and 550 bp for the wild-type and N-terminal mutant Prnp-specific signals. After 21 cycles in a thermal cycler (Perkin Elmer/ Cetus, USA; 45 s at 95°C, 45 s at 62°C and 1 min at 72°C) followed by 7 min at 72°C and subsequent cooling to 4°C, 5 41 samples were electrophoresed through agarose gels. After drying, the gels were analyzed using a Phosphorlmager (Molecular Dynamics, USA). Copy numbers were estimated by comparison with control reactions containing appropriate cloned standards run in parallel.
Northern blots
Total brain RNA was prepared essentially as described (Chomczynski and Sacchi, 1987) and electrophoresed through a 1%7 agarose gel. Prehybridization and hybridization were according the Quikhyb protocol (Stratagene). A 140 nucleotide single-stranded DNA probe was prepared by linear amplification for 10 cycles of a NcoI-AvaII murine PrP cDNA fragment comprising the sequence from codon 84 (His) to codon 145 (Glu), using a primer hybridizing to the DNA plus strand (pr del-: 5'tccccagcatgtagccaccaagg3'). The ,B-actin probe, an EcoRI-Hindlll fragment of chicken f-actin cDNA (Cleveland et al., 1980) , was 32p labeled by the random primer method (Prime-It, Stratagene).
Western blot analysis Electrophoresis of brain homogenates and blotting were carried out essentially as described (BiUeler et al., 1994) . The antibodies used were R073, a rabbit polyclonal antiserum raised against PrP27-30 from hamster (Serban et al., 1990) , 1B3, a rabbit polyclonal serum directed against SAF (aggregated PrP) from mouse (Farquhar et al., 1989 ) and R3430. a rabbit polyclonal serum directed against the N-terminal peptide PI from hamster PrP27-30 (GQGGGTHNQWNKP, identical to the murine sequence comprising amino acids 89-102) ), at a 1:2000 dilution.
Determination of PrPSC
Brain homogenates (10%7) in 0.32 M sucrose were adjusted to 0.5% in SST buffer (20 mM Tris-HCI pH 7.5, 2% N-lauryl sodium sarcosine, 0.32 M sucrose) and further homogenized by drawing through a 26 gauge needle. Of this. 900 ,1u were digested with 5 4g/ml proteinase K for 15 min at 370C. After adding 10 ,ul of 0.1 M phenylmethylsulfonyl fluoride, 800 p1 were centrifuged at 100 000 g for 2 h at 10°C. The final pellet was resuspended in 80 ,tl of SST and 40 ,d of 5X SDS loading buffer containing I % mercaptoethanol and heated for 5 min in a boiling waterbath.
Inoculations and scrapie diagnosis Inocula were prepared by incubating cleared 10% brain homogenates for 20 min at 80°C and subsequently diluting in phosphate-buffered saline (PBS)-5%7 BSA. Mice were inoculated intracerebrally with 30 p1 of 1% brain extract, which was prepared from terminally scrapie-sick mice (CD-I) inoculated with mouse-adapted (RML) prions as described previously (Bueler et al., 1993) . The animals were monitored at weekly intervals for the first 40 days p.i. and at 2-day intervals thereafter.
